DOCSLIB.ORG

Epileptic Spasms Are a Feature of DEPDC5 Mtoropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Epileptic spasms are a feature of DEPDC5 mTORopathy Gemma L. Carvill, PhD ABSTRACT Douglas E. Crompton, Objective: To assess the presence of DEPDC5 mutations in a cohort of patients with epileptic PhD, MBBS spasms. Brigid M. Regan, BSc Methods: We performed DEPDC5 resequencing in 130 patients with spasms, segregation anal- (Hons) ysis of variants of interest, and detailed clinical assessment of patients with possibly and likely Jacinta M. McMahon, pathogenic variants. BSc (Hons) DEPDC5 Julia Saykally Results: We identified 3 patients with variants in in the cohort of 130 patients with DEPDC5 Matthew Zemel, BS spasms. We also describe 3 additional patients with alterations and epileptic spasms: 2 Amy L. Schneider, MGen from a previously described family and a third ascertained by clinical testing. Overall, we describe DEPDC5 Couns 6 patients from 5 families with spasms and variants; 2 arose de novo and 3 were Leanne Dibbens, PhD familial. Two individuals had focal cortical dysplasia. Clinical outcome was highly variable. Katherine B. Howell, Conclusions: While recent molecular findings in epileptic spasms emphasize the contribution of de MBBS (Hons), novo mutations, we highlight the relevance of inherited mutations in the setting of a family history BMedSc of focal epilepsies. We also illustrate the utility of clinical diagnostic testing and detailed pheno- Simone Mandelstam, typic evaluation in characterizing the constellation of phenotypes associated with DEPDC5 alter- MBChB ations. We expand this phenotypic spectrum to include epileptic spasms, aligning DEPDC5 Richard J. Leventer, epilepsies more with the recognized features of other mTORopathies. Neurol Genet 2015;1:e17; MBBS, PhD doi: 10.1212/NXG.0000000000000016 A. Simon Harvey, MD Saul A. Mullen, MBBS, GLOSSARY PhD ExAC 5 Exome Aggregation Consortium; FCD 5 focal cortical dysplasia; FFEVF 5 familial focal epilepsy with variable foci; 5 5 5 Samuel F. Berkovic, MD, MAF minor allele frequency; mTOR mammalian target of rapamycin; TSC tuberous sclerosis complex. FRS Autosomal dominant mutations in DEPDC5 cause familial focal epilepsy with variable foci Joseph Sullivan, MD 1,2 Ingrid E. Scheffer, MBBS, (FFEVF). FFEVF is characterized by seizures arising from different cortical regions in dif- 1,3–7 PhD* ferent family members, and onset ranges from infancy to adulthood. Clinical presentation 1,2 Heather C. Mefford, MD, is highly variable and reduced penetrance of ;66%isusual. Families may show patterns PhD* that are effectively subsets of FFEVF, such as a phenotypically homogeneous pattern of autosomal dominant nocturnal frontal lobe epilepsy; individuals with rolandic epilepsy have also been described.1,2,8–10 Recently, DEPDC5 mutations were reported in patients with var- Correspondence to Dr. Mefford: ious brain malformations, challenging the long-held distinction between lesional and nonle- – [email protected] or sional epilepsies.11 13 Dr. Scheffer: [email protected] DEPDC5 forms part of the GATOR1 complex, a negative regulator of the mammalian target 14 Supplemental data of rapamycin (mTOR) pathway. Mutations in other mTOR pathway proteins TSC1 and at Neurology.org/ng *These authors contributed equally to the manuscript. From the Division of Genetic Medicine (G.L.C., J. Saykally, M.Z., H.C.M.), Department of Pediatrics, University of Washington, Seattle; Epilepsy Research Centre (D.E.C., B.M.R., J.M.M., A.L.S., S.A.M., S.F.B., I.E.S.), Department of Medicine, The University of Melbourne, Austin Health, Melbourne, Australia; Neurology Department (D.E.C.), Northern Health, Melbourne, Australia; Epilepsy Research Program (L.D.), School of Pharmacy and Medical Sciences, and Sansom Institute for Health Research (L.D.), University of South Australia, Adelaide, Australia; Department of Neurology (K.B.H., R.J.L., A.S.H., I.E.S.), Royal Children’s Hospital, Melbourne, Australia; Florey Institute of Neuroscience and Mental Health (K.B.H., S.M., R.J.L., A.S.H., S.A.M., I.E.S.), Melbourne, Australia; Murdoch Childrens Research Institute (K.B.H., R.J.L., A.S.H.), Melbourne, Australia; Department of Paediatrics (S.M., R.J.L., A.S.H.) and Department of Radiology (S.M.), The University of Melbourne, Melbourne, Australia; and Epilepsy Division (J. Sullivan), Department of Neurology and Pediatrics, University of California, San Francisco. Funding information and disclosures are provided at the end of the article. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by the authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially. Neurology.org/ng © 2015 American Academy of Neurology 1 ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. 2 Table 1 Clinical and molecular features in patients with DEPDC5 variants and epileptic spasms Protein change Age cDNA change (PolyPhen-2, SIFT, studied, Epilepsy Seizure Seizure Other Ped Ref (GERP) Grantham) sex syndrome onset offset Development Seizure types (onset) EEG/video EEG, age MRI Treatment features A:III:2 c.2390delA p.Gln797Argfs*18; 3 y, M IS 2 mo Ongoing Global DD; IS, asymmetric (2 mo); 4 mo: interictal GSW and low-voltage fast Right Improved with ASD (NA) NA regression FDS (9 mo) activity. In spasms: high-voltage biphasic temporal prednisolone. Refractory slow waves then low-voltage fast activity. FCD to PB, CZP, and VGB. FDS: improved with TPM and CBZ. Right anterior temporal lobectomy Neurology: Genetics scheduled. 4–24 mo: right focal slowing, right temporal Mild left interictal epileptiform discharges leg weakness 2 y 2 mo: as at 4–24 mo plus subclinical electrographic seizures arising from right anterior temporal region B:III:2 c.1555C.T p.Gln519*; NA 30 y, M IS 6 wk Ongoing Global DD; IS (6 wk); FDS (3 y); 28 y: generalized background slowing, ND Refractory to CBZ, CZP, Autistic (6.01) regression; FDS/TCS (3 y); multifocal interictal sharp-slow discharges, LEV, LTG, prednisolone, features moderate- myoclonus maximal centrally and posteriorly, usually and VPA severe ID bisynchronous, sometimes with background attenuation. Similar discharges with asymmetric myoclonic jerks and negative myoclonus. C:III:3 c.3092C.A p.Pro1031His; 16 y, F Late-onset 2 y 8 mo Ongoing Speech and Asymmetric flexor 7 y 4 mo: interictal epileptiform spikes and Normal Refractory to CBZ, CLB, Nil (5.31) 0.971, 0.01, 23 epileptic language delay; spasms (2 y 8 mo); sharp waves from both temporal and ETX, KD, LCM, LTG, NZP, spasms regression; mild reflex tonic seizures posterior regions in sleep. GSW, GPSW, and TPM, VGB, VPA, and ZSM ID precipitated by startle GPFA in slow wave sleep. Ictal EEG: (1) with (10 y); atypical spasms: polyphasic, rhythmic 2 Hz delta, absences (11 y); TCS maximal in midline, often with superimposed (12 y) fast beta; (2) with reflex tonic seizures: generalized decrements and LVFA; and (3) with absences: GSW at 2–3 Hz. 9 y 5 mo: as above plus background slowing, 10 y: left lateral temporal interictal left central sharp-slow trains and corticectomy, normal frontotemporal delta, GSW with left histopathology, no temporal lead-in improvement D:II:1 c.842A.T Tyr281Phe; 0.997, 5 y, F IS 3 mo Ongoing Speech and IS; tonic seizures 14 mo: hypsarrhythmia with focal fast Left Refractory to B6, ACTH, Right HP (5.05) 0.02, 22 (rare) language delay, (27 mo) activity in left frontocentral regions. frontal PB, VGB, and KD s/p hemispherotomy Electroclinical spasms with generalized FCD spike/wave and pseudonormalization. 27 mo: (s/p left frontal lobectomy) hypsarrhythmia. Head drops, brief tonic seizures, and tonic eye deviation associated with low-amplitude fast activity. E:IV:21 c.19311G.A NA 34 y, F IS, OLE 2 mo FDS Normal IS (8 wk); FDS (11 y) 5 mo: multifocal and generalized interictal Normal Spasms: ceased with Nil ongoing, polyspike-wave discharges prednisolone; FDS: partial spasms response to CBZ ceased at 6 mo 8 mo: normal 34 y: nonspecific episodic generalized slowing, otherwise normal Continued ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. Table 1 Continued ª Protein change Age cDNA change (PolyPhen-2, SIFT, studied, Epilepsy Seizure Seizure Other 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited. Ped Ref (GERP) Grantham) sex syndrome onset offset Development Seizure types (onset) EEG/video EEG, age MRI Treatment features E:IV:41 c.19311G.A NA 16 y, M IS 6 wk 6 mo Global DD; ID IS (6 wk) 5 mo: background slowing, multifocal Normal Controlled on VGB Autistic spike-wave and polyspike-wave activity, features left occipital electrographic seizure 3 y 7 mo: within normal limits Infantile esotropia Abbreviations: ACTH 5 adrenocorticotropic hormone; ASD 5 autistic spectrum disorder; B6 5 pyridoxine; CBZ 5 carbamazepine; CLB 5 clobazam; CZP 5 clonazepam; DD 5 developmental delay; ETX 5 ethosuxamide; FCD 5 focal cortical dysplasia; FDS 5 focal dyscognitive seizure; FDS/TCS 5 focal dyscognitive seizure evolving to a bilateral convulsive/tonic-clonic seizure; FSRA 5 focal seizure with retained awareness; GERP 5 Genome Evolutionary Rate Profiling; GPFA 5 generalized paroxysmal fast activity; GPSW 5 generalized polyspike-wave; GSW 5 generalized spike-wave; HP 5 hemiparesis; ID 5 intellectual disability; IS 5 infantile spasms; KD 5 ketogenic diet; LCM 5 lacosamide; LEV 5 levetiracetam; LTG 5 lamotrigine; LVFA 5 low-voltage fast activity; NA 5 not applicable; ND 5 not done; NZP 5 nitrazepam; OLE 5 occipital lobe epilepsy; PB 5 phenobarbitone; Ped Ref 5 pedigree reference; s/p 5 status post; TCS 5 tonic-clonic seizure; TPM 5 topiramate; VGB 5 vigabatrin; VNS 5 vagal nerve stimulator; VPA 5 valproate; ZSM 5 zonisamide.
Recommended publications
  • Acute Knockdown of Depdc5 Leads to Synaptic Defects in Mtor-Related Epileptogenesis

    Acute Knockdown of Depdc5 Leads to Synaptic Defects in Mtor-Related Epileptogenesis

    Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis Antonio de Fusco, Maria Sabina Cerullo, Antonella Marte, Caterina Michetti, Alessandra Romei, Enrico Castroflorio, Stéphanie Baulac, Fabio Benfenati To cite this version: Antonio de Fusco, Maria Sabina Cerullo, Antonella Marte, Caterina Michetti, Alessandra Romei, et al.. Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis. Neurobiology of Disease, Elsevier, In press, 10.1016/j.nbd.2020.104822. hal-02498215 HAL Id: hal-02498215 https://hal.sorbonne-universite.fr/hal-02498215 Submitted on 4 Mar 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Journal Pre-proof Acute knockdown of Depdc5 leads to synaptic defects in mTOR- related epileptogenesis Antonio De Fusco, Maria Sabina Cerullo, Antonella Marte, Caterina Michetti, Alessandra Romei, Enrico Castroflorio, Stephanie Baulac, Fabio Benfenati PII: S0969-9961(20)30097-8 DOI: https://doi.org/10.1016/j.nbd.2020.104822 Reference: YNBDI 104822 To appear in: Neurobiology of Disease Received date: 13 November 2019 Revised date: 2 February 2020 Accepted date: 26 February 2020 Please cite this article as: A. De Fusco, M.S. Cerullo, A. Marte, et al., Acute knockdown of Depdc5 leads to synaptic defects in mTOR-related epileptogenesis, Neurobiology of Disease(2020), https://doi.org/10.1016/j.nbd.2020.104822 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.
  • DEPDC5 Takes a Second Hit in Familial Focal Epilepsy

    DEPDC5 Takes a Second Hit in Familial Focal Epilepsy

    DEPDC5 takes a second hit in familial focal epilepsy Matthew P. Anderson J Clin Invest. 2018;128(6):2194-2196. https://doi.org/10.1172/JCI121052. Commentary Loss-of-function mutations in a single allele of the gene encoding DEP domain–containing 5 protein (DEPDC5) are commonly linked to familial focal epilepsy with variable foci; however, a subset of patients presents with focal cortical dysplasia that is proposed to result from a second-hit somatic mutation. In this issue of the JCI, Ribierre and colleagues provide several lines of evidence to support second-hit DEPDC5 mutations in this disorder. Moreover, the authors use in vivo, in utero electroporation combined with CRISPR-Cas9 technology to generate a murine model of the disease that recapitulates human manifestations, including cortical dysplasia–like changes, focal seizures, and sudden unexpected death. This study provides important insights into familial focal epilepsy and provides a preclinical model for evaluating potential therapies. Find the latest version: https://jci.me/121052/pdf COMMENTARY The Journal of Clinical Investigation DEPDC5 takes a second hit in familial focal epilepsy Matthew P. Anderson Departments of Neurology and Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Boston Children’s Hospital Intellectual and Developmental Disabilities Research Center, Boston, Massachusetts, USA. Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, USA. These detailed genetic and biochemical correlations in the human tissues then led Loss-of-function mutations in a single allele of the gene encoding DEP them to design tests of causality in a mouse domain–containing 5 protein (DEPDC5) are commonly linked to familial model, in which they reconstituted many focal epilepsy with variable foci; however, a subset of patients presents with features of the human disorder.
  • Epilepsy Syndromes E9 (1)

    Epilepsy Syndromes E9 (1)

    EPILEPSY SYNDROMES E9 (1) Epilepsy Syndromes Last updated: September 9, 2021 CLASSIFICATION .......................................................................................................................................... 2 LOCALIZATION-RELATED (FOCAL) EPILEPSY SYNDROMES ........................................................................ 3 TEMPORAL LOBE EPILEPSY (TLE) ............................................................................................................... 3 Epidemiology ......................................................................................................................................... 3 Etiology, Pathology ................................................................................................................................ 3 Clinical Features ..................................................................................................................................... 7 Diagnosis ................................................................................................................................................ 8 Treatment ............................................................................................................................................. 15 EXTRATEMPORAL NEOCORTICAL EPILEPSY ............................................................................................... 16 Etiology ................................................................................................................................................ 16
  • Handbook of EEG INTERPRETATION This Page Intentionally Left Blank Handbook of EEG INTERPRETATION

    Handbook of EEG INTERPRETATION This Page Intentionally Left Blank Handbook of EEG INTERPRETATION

    Handbook of EEG INTERPRETATION This page intentionally left blank Handbook of EEG INTERPRETATION William O. Tatum, IV, DO Section Chief, Department of Neurology, Tampa General Hospital Clinical Professor, Department of Neurology, University of South Florida Tampa, Florida Aatif M. Husain, MD Associate Professor, Department of Medicine (Neurology), Duke University Medical Center Director, Neurodiagnostic Center, Veterans Affairs Medical Center Durham, North Carolina Selim R. Benbadis, MD Director, Comprehensive Epilepsy Program, Tampa General Hospital Professor, Departments of Neurology and Neurosurgery, University of South Florida Tampa, Florida Peter W. Kaplan, MB, FRCP Director, Epilepsy and EEG, Johns Hopkins Bayview Medical Center Professor, Department of Neurology, Johns Hopkins University School of Medicine Baltimore, Maryland Acquisitions Editor: R. Craig Percy Developmental Editor: Richard Johnson Cover Designer: Steve Pisano Indexer: Joann Woy Compositor: Patricia Wallenburg Printer: Victor Graphics Visit our website at www.demosmedpub.com © 2008 Demos Medical Publishing, LLC. All rights reserved. This book is pro- tected by copyright. No part of it may be reproduced, stored in a retrieval sys- tem, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher. Library of Congress Cataloging-in-Publication Data Handbook of EEG interpretation / William O. Tatum IV ... [et al.]. p. ; cm. Includes bibliographical references and index. ISBN-13: 978-1-933864-11-2 (pbk. : alk. paper) ISBN-10: 1-933864-11-7 (pbk. : alk. paper) 1. Electroencephalography—Handbooks, manuals, etc. I. Tatum, William O. [DNLM: 1. Electroencephalography—methods—Handbooks. WL 39 H23657 2007] RC386.6.E43H36 2007 616.8'047547—dc22 2007022376 Medicine is an ever-changing science undergoing continual development.
  • Psychogenic Seizurespsychogenicseizures

    Psychogenic Seizurespsychogenicseizures

    PsychogenicPsychogenicSeizuresSeizures MMaartrtiinnSaSalliinsnskykyMM..DD.. PoPortrtllaandndVVAAMMCCEEpipillepsyepsyCCententererooffEExxcecellllenceence OreOreggoonnHeaHealltthh&&SciScienceenceUUninivverersisittyy …You’d better ask the doctors here about my illness, sir. Ask them whether my fit was real or not. TTheheBBrrootthershersKaKararamamazzoovv;;FF..DDooststooevevskskyy,,11888811 Psychogenic Seizures Psychogenic seizures (PNES) PNES in Veterans Treatment and Prognosis *excluding headache, back pain Epilepsy Cases per 100 persons 0.2 0.4 0.6 0.8 1.2 1.4 neurologists worldwide* The most common problem faced by 0 1 Epilepsy Neuropathy Cerebrovascular Dementia ~1% of the world burden of disease (WHO) Prevalence (per 100 persons) Murray et al; WHO, 1994Singhai; Arch Neurol 1998 Kobau; MMR, August Medina; 2008 J Neurol Sci 2007 Speaec 08%Sprevalence ~0.85% US prevalence ~0.85%US Disorders that may mimic epilepsy (adults) Cardiovascular events (syncope) » Vasovagal attacks (vasodepressor syncope) » Arrhythmias (Stokes-Adams attacks) Movement disorders » Paroxysmal choreoathetosis » Myoclonus, tics, habit spasms Migraine - confusional, basilar Sleep disorders (parasomnias) Metabolic disorders (hypoglycemia) Psychological disorders » Psychogenic seizures Non-Epileptic Seizures (NES) A transient alteration in behavior resembling an epileptic seizure but not due to paroxysmal neuronal discharges; –Psychogenic Seizures (PNES) without other physiologic abnormalities with probable psychological origin Non-Epileptic Seizures (NES) Seizures Epileptic
  • ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions

    ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions

    ILAE Classification and Definition of Epilepsy Syndromes with Onset in Childhood: Position Paper by the ILAE Task Force on Nosology and Definitions N Specchio1, EC Wirrell2*, IE Scheffer3, R Nabbout4, K Riney5, P Samia6, SM Zuberi7, JM Wilmshurst8, E Yozawitz9, R Pressler10, E Hirsch11, S Wiebe12, JH Cross13, P Tinuper14, S Auvin15 1. Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesu’ Children’s Hospital, IRCCS, Member of European Reference Network EpiCARE, Rome, Italy 2. Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester MN, USA. 3. University of Melbourne, Austin Health and Royal Children’s Hospital, Florey Institute, Murdoch Children’s Research Institute, Melbourne, Australia. 4. Reference Centre for Rare Epilepsies, Department of Pediatric Neurology, Necker–Enfants Malades Hospital, APHP, Member of European Reference Network EpiCARE, Institut Imagine, INSERM, UMR 1163, Université de Paris, Paris, France. 5. Neurosciences Unit, Queensland Children's Hospital, South Brisbane, Queensland, Australia. Faculty of Medicine, University of Queensland, Queensland, Australia. 6. Department of Paediatrics and Child Health, Aga Khan University, East Africa. 7. Paediatric Neurosciences Research Group, Royal Hospital for Children & Institute of Health & Wellbeing, University of Glasgow, Member of European Refence Network EpiCARE, Glasgow, UK. 8. Department of Paediatric Neurology, Red Cross War Memorial Children’s Hospital, Neuroscience Institute, University of Cape Town, South Africa. 9. Isabelle Rapin Division of Child Neurology of the Saul R Korey Department of Neurology, Montefiore Medical Center, Bronx, NY USA. 10. Programme of Developmental Neurosciences, UCL NIHR BRC Great Ormond Street Institute of Child Health, Department of Clinical Neurophysiology, Great Ormond Street Hospital for Children, London, UK 11.
  • The Genetics of Bipolar Disorder

    The Genetics of Bipolar Disorder

    Molecular Psychiatry (2008) 13, 742–771 & 2008 Nature Publishing Group All rights reserved 1359-4184/08 $30.00 www.nature.com/mp FEATURE REVIEW The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions A Serretti and L Mandelli Institute of Psychiatry, University of Bologna, Bologna, Italy Bipolar disorder (BP) is a complex disorder caused by a number of liability genes interacting with the environment. In recent years, a large number of linkage and association studies have been conducted producing an extremely large number of findings often not replicated or partially replicated. Further, results from linkage and association studies are not always easily comparable. Unfortunately, at present a comprehensive coverage of available evidence is still lacking. In the present paper, we summarized results obtained from both linkage and association studies in BP. Further, we indicated new potential interesting genes, located in genome ‘hot regions’ for BP and being expressed in the brain. We reviewed published studies on the subject till December 2007. We precisely localized regions where positive linkage has been found, by the NCBI Map viewer (http://www.ncbi.nlm.nih.gov/mapview/); further, we identified genes located in interesting areas and expressed in the brain, by the Entrez gene, Unigene databases (http://www.ncbi.nlm.nih.gov/entrez/) and Human Protein Reference Database (http://www.hprd.org); these genes could be of interest in future investigations. The review of association studies gave interesting results, as a number of genes seem to be definitively involved in BP, such as SLC6A4, TPH2, DRD4, SLC6A3, DAOA, DTNBP1, NRG1, DISC1 and BDNF.
  • Mesial Frontal Epilepsy

    Mesial Frontal Epilepsy

    Epikpsia, 39(Suppl. 4):S49-S61. 1998 Lippincon-Raven Publishers, Philadelphia 0 International League Against Epilepsy Mesial Frontal Epilepsy Norman K. So Oregon Comprehensive Epilepsy Program, Legacy Portland Hospitals, Portland, Oregon, U.S.A. Summary: The mesiofrontal cortex comprises a number of occur. The task of localization of the epileptogenic zone can be distinct anatomic and functional areas. Structural lesions and challenging, whether EEG or imaging methods are used. Suc- cortical dysgenesis are recognized causes of mesial frontal epi- cessful localization can lead to a rewarding outcome after epi- lepsy, but a specific gene defect may also be important, as seen lepsy surgery, particularly in those with an imaged lesion. in some forms of familial frontal lobe epilepsy. The predomi- Key Words: Mesial frontal epilepsy-cingulate gyrus- nant seizure manifestations, which are not necessarily strictly Supplementary motor area-Absence seizure-Hypermotor correlated with a specific ictal onset zone, are absence, hyper- seizure-Postural tonic seizure-Epilepsy surgery. motor, and postural tonic seizures. Other seizure types also FUNCTIONAL ANATOMY convolution. Traditional cytoarchitectonics have further subdivided this anterior frontal region. The frontal pole The frontal lobe is the largest lobe in the brain, ac- refers to the anterior most portion of the frontal lobe, but counting for one-third to one-half of total brain volume there is little consensus on how far back this extends. and weight. On the medial surface, the most important One or more curved.sulci are seen anterior and inferior to landmark is the cingulate sulcus (Fig. 1). This runs as an the cingulate sulcus, called the superior and inferior ros- inverted “C” following the contour of the corpus callo- tral sulci.
  • Stranded Breaks in Drosophila Youheng Wei1,2†, Lucia Bettedi1†, Chun-Yuan Ting1, Kuikwon Kim1, Yingbiao Zhang1, Jiadong Cai2, Mary a Lilly1*

    Stranded Breaks in Drosophila Youheng Wei1,2†, Lucia Bettedi1†, Chun-Yuan Ting1, Kuikwon Kim1, Yingbiao Zhang1, Jiadong Cai2, Mary a Lilly1*

    RESEARCH ARTICLE The GATOR complex regulates an essential response to meiotic double- stranded breaks in Drosophila Youheng Wei1,2†, Lucia Bettedi1†, Chun-Yuan Ting1, Kuikwon Kim1, Yingbiao Zhang1, Jiadong Cai2, Mary A Lilly1* 1Cell Biology and Neurobiology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States; 2College of Bioscience and Biotechnology, Yangzhou University, Yangzhou, China Abstract The TORC1 regulator GATOR1/SEACIT controls meiotic entry and early meiotic events in yeast. However, how metabolic pathways influence meiotic progression in metazoans remains poorly understood. Here we examine the role of the TORC1 regulators GATOR1 and GATOR2 in the response to meiotic double-stranded breaks (DSB) during Drosophila oogenesis. We find that in mutants of the GATOR2 component mio, meiotic DSBs trigger the constitutive downregulation of TORC1 activity and a permanent arrest in oocyte growth. Conversely, in GATOR1 mutants, high TORC1 activity results in the delayed repair of meiotic DSBs and the hyperactivation of p53. Unexpectedly, we found that GATOR1 inhibits retrotransposon expression in the presence of meiotic DSBs in a pathway that functions in parallel to p53. Thus, our studies have revealed a link between oocyte metabolism, the repair of meiotic DSBs and retrotransposon expression. DOI: https://doi.org/10.7554/eLife.42149.001 *For correspondence: [email protected] Introduction †These authors contributed We are interested in understanding how metabolism impacts meiotic progression during oogenesis. equally to this work Target of Rapamycin Complex 1 (TORC1) is a multi-protein complex that functions as a master regu- lator of metabolism (Loewith and Hall, 2011; Laplante and Sabatini, 2012a; Jewell and Guan, Competing interests: The 2013).
  • Treatment for Patients with Lennox-Gastaut Syndrome Roundtable

    Treatment for Patients with Lennox-Gastaut Syndrome Roundtable

    Treatment for Patients with Lennox-Gastaut Syndrome Roundtable Video 3/5 – Diagnosis, Issues and Seizures Dr. Randa Jarrar Pediatric Epileptologist at Phoenix Children's Hospital Given the poor prognosis of Lennox-Gastaut Syndrome with regards to seizure control and cognitive outcome, it is very important to apply that term with caution. How do we go about diagnosing it and what kind of investigations do we have to do once we diagnosis it? Well, the diagnosis really relies on that classic triad of many seizure types, mental retardation, and the classic EEG features that we just went over, mainly the slow spike in wave. Some people consider the presence of ten-hertz fast activity as an essential for diagnosis. This can be either associated with atonic seizures or can occur with minimal clinical manifestations, such as apnea or perhaps truncal rigidity, that can be seen mainly during non-REM sleep. As we said, the diagnosis relies heavily on the EEG. Although it sounds easy to diagnosis since you have all these features, the features may not be very clear early at onset. Why? The cause, the history, the seizure types, the EEG features, are not pathognomonic for Lennox-Gastaut Syndrome. They are shared by other epilepsy syndromes and can occur in other seizure types. In addition, the core seizure types may not be present at onset. You can initially have focal seizure or the patient may present with myoclonic seizures, which can complicate the picture. The EEG features we talked about extensively, but I just want to emphasize that a sleep recording is almost essential, not just a sleep recording, but a video sleep recording.
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer

    Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer

    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
  • Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary

    Engineered Type 1 Regulatory T Cells Designed for Clinical Use Kill Primary

    ARTICLE Acute Myeloid Leukemia Engineered type 1 regulatory T cells designed Ferrata Storti Foundation for clinical use kill primary pediatric acute myeloid leukemia cells Brandon Cieniewicz,1* Molly Javier Uyeda,1,2* Ping (Pauline) Chen,1 Ece Canan Sayitoglu,1 Jeffrey Mao-Hwa Liu,1 Grazia Andolfi,3 Katharine Greenthal,1 Alice Bertaina,1,4 Silvia Gregori,3 Rosa Bacchetta,1,4 Norman James Lacayo,1 Alma-Martina Cepika1,4# and Maria Grazia Roncarolo1,2,4# Haematologica 2021 Volume 106(10):2588-2597 1Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 2Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine, Stanford, CA, USA; 3San Raffaele Telethon Institute for Gene Therapy, Milan, Italy and 4Center for Definitive and Curative Medicine, Stanford School of Medicine, Stanford, CA, USA *BC and MJU contributed equally as co-first authors #AMC and MGR contributed equally as co-senior authors ABSTRACT ype 1 regulatory (Tr1) T cells induced by enforced expression of interleukin-10 (LV-10) are being developed as a novel treatment for Tchemotherapy-resistant myeloid leukemias. In vivo, LV-10 cells do not cause graft-versus-host disease while mediating graft-versus-leukemia effect against adult acute myeloid leukemia (AML). Since pediatric AML (pAML) and adult AML are different on a genetic and epigenetic level, we investigate herein whether LV-10 cells also efficiently kill pAML cells. We show that the majority of primary pAML are killed by LV-10 cells, with different levels of sensitivity to killing. Transcriptionally, pAML sensitive to LV-10 killing expressed a myeloid maturation signature.